50th Anniversary Symposium

Discovery of Serum Creatine Kinase as a Diagnostic Marker of Muscular Dystrophy

Organizers

Ichiro Kanazawa Shin'ichi Takeda Shoji Tsuji Teruo Shimizu Shinichi Kohsaka

9 and 10, January 2009 TOSHI CENTER HOTEL

2-4-1 Hirakawa-cho, Chiyoda-ku, Tokyo 102-0093, Japan

TEL. 03(3265)8211 FAX. 03(3262)1705

CK50周年記念事業

平成21年1月9日(金) 都市センターホテル

特別講演

会場 3階 コスモス I ホール

座長 清水 輝夫 (帝京大学医学部長)

17:00 - 17:10

開会挨拶 金澤 一郎

(日本学術会議会長)

17:10 - 17:40

特別講演 杉田 秀夫

(国立精神・神経センター名誉総長)

演 題 「血清 CK 発見から 5 0 年」

懇親会

会場 3階 コスモス II ホール

18:00 - 20:00

Saturday, 10 January: morning

8:30 Opening remarks

Shin'ichi Takeda

8:40 - 10:40 Session 1 / Congenital muscular dystrophy and myotonic dystrophy Shin'ichi Takeda, chairman

8:40

Tatsushi Toda

Division of Clinical Genetics, Osaka University Graduate School of Medicine, 2-2-B9, Yamadaoka, Suita, Osaka 565-0871, Japan

Fukutinopathy and dystroglycanopathy

9:10

Tamao Endo

Tokyo Metropolitan Institute of Gerontology, Foundation for Research on Aging and Promotion of Human Welfare, Itabashi-ku, Tokyo 173-0015, Japan

Defective glycosylation in congenital muscular dystrophy

9:35

Kiichiro Matsumura, Fumiaki Saito, Yuko Saito-Arai, Miki Ikeda, Teruo Shimizu Department of Neurology and Neuroscience, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan

Processing of dystroglycan in physiological and pathological conditions

9:55

Atsushi Suzuki

Department of Molecular Biology, Yokohama City University Graduate School of Medical Science

3-9, Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan

A novel regulatory mechanism of the dystroglycan complex in epithelial cell polarity development

10:15

Shoichi Ishiura¹, Yoshihiro Kino², Noboru Sasagawa¹, Nobuyuki Nukina²

¹Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo 153-8902, Japan

²Laboratory for Structural Neuropathology, RIKEN Brain Science Institute, Wako, Saitama 351-0198, Japan

MBNL and CELF proteins regulate alternative splicing of the skeletal muscle chloride channel CLC-1/CLCN1

10:40 - 10:55 Coffee breaks

10:55 - 11:45 Session 2 / Preparing for therapies in inherited neuromuscular diseases Ichizo Nishino, chairman

10:55

Kate Bushby

Institute of Human Genetics, University of Newcastle upon Tyne, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ UK

Accelerating the path to treatments for inherited neuromuscular diseases

11:25

Mitsuru Kawai

Department of Neurology, National Hospital Organization Higashi-saitama Hospital, 4147 Kurohama, Hasuda-shi, Saitama 349-0196, Japan

Muscular dystrophy specific QOL scale MDQoL-60

11:45 - 13:00 Lunch

Saturday, 10 January: afternoon

13:00 - 16:50 Session 3 / Molecular pathogenesis and treatment of muscular dystrophy Yoshihide Sunada, chairman

13:00

Louis M. Kunkel, Emanuela Gussoni, Peter Kang, Hart Lidov, Genri Kawahara, Basil Darras, Frederic Shapiro, Joanne Kurtzberg, Barbara Bambach

The Department of Pediatrics and Genetics, Harvard Medical School, Howard Hughes Medical Institute, Children's Hospital Boston, Boston, MA 02115, USA

Cord blood transplant in DMD and zebrafish without FKRP

13:30

H. Lee Sweeney

Department of Physiology University of Pennsylvania School of Medicine, 3700 Hamilton Walk, Philadelphia, PA 19104-6085 USA

Premature stop codon suppression: A therapeutic strategy for the treatment of a subset of patients with Duchenne muscular dystrophy and other genetic disorders

14:00

Rvoichi Matsuda

Department of Life Sciences, University of Tokyo, 3-8-1 Komaba, Tokyo 153-8902, Japan Readthrough therapy of muscular dystrophy using negamycin and negamycin-related molecules

14:25 - 14:40 Coffee breaks

Tatsushi Toda, chairman

1/1//

Yoshihide Sunada¹, Yutaka Ohsawa¹, Kunihiro Tsuchida² and Sumihare Noji³
¹Division of Neurology, Department of Internal Medicine, Kawasaki Medical School 84-9
Matsushima, Kurashiki-City, Okayama 701-0192 Japan

²Division for Therapies against Intractable Diseases, Institute for Comprehensive Medical Science, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake-City, Aichi 470-1192 Japan

³Department of Biological Science and Technology, Faculty of Engineering, The University of Tokushima, 2-1 Minami-Jyosanjima-cho, Tokushima-City, Tokushima 770-8506 Japan

Development and application of anti-myostatin therapy for muscular dystrophy

15:05

Ichizo Nishino, May Christine V. Malicdan, Satoru Noguchi

Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), 4-1-1 Ogawa-higashi, Kodaira, Tokyo 187-8502, Japan Sweetening the therapy for distal myopathy with rimmed vacuoles/hereditary inclusion body myopathy

15:30

Masafumi Matsuo

Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan

Treatment of Duchenne muscular dystrophy with antisense oligonucleotides

15:55

Eric P. Hoffman¹, Toshifumi Yokota¹, Qi-long Lu², Terence Partridge¹, Masanori Kobayashi³, Akinori Nakamura³, Nobuyuki Urasawa³, and Shin'ichi Takeda³
¹Research Center for Genetic Medicine, Children's National Medical Center, 111 Michigan Ave, NW, Washington, District of Columbia 20010, USA
²McColl-Lockwood Laboratory for Muscular Dystrophy Research, Neuromuscular/ALS Center,

Carolinas Medical Center, 1000 Blythe Blvd. Charlotte, NC 28231, USA ³Department of Molecular Therapy, National Institute of Neuroscience, National Center of

Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), 4-1-1 Ogawa-higashi, Kodaira, Tokyo 187-8502, Japan *Efficacy of systemic morpholino exon-skipping in Duchenne muscular dystrophy*

Efficacy of systemic morpholino exon-skipping in Duchenne muscular dystrophy dogs

16:25

Shin'ichi Takeda

Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), 4-1-1 Ogawa-higashi, Kodaira, Tokyo 187-8502, Japan *Advances of molecular therapy research on dystrophin-deficient muscular dystrophy models*

16:50 Closing remarks

Ikuya Nonaka